A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)

Clinical Studies - Mar 30, 2016 - Dec 31, 2099

Ongoing

Project leader: Fehr Martin
Members: Demmer-Steingruber Ruth, Müller Fiona

Adjuvant immunotherapy with anti-PD-1 monoclonal antibody Pembrolizumab (MK-3475) versus placebo after complete resection of high-risk Stage III melanoma: A randomized, double- blind Phase 3 trial of the EORTC Melanoma Group.

Clinical Studies - Feb 15, 2016 - Dec 31, 2099

Ongoing

Project leader: Fehr Martin
Members: Hutter Franziska, Müller Fiona

A study evaluating the pregnancy outcomes and safety of interrupting endocrine therapy for young women with endocrine responsive breast cancer who desire pregnancy

Clinical Studies - Mar 27, 2015 - Dec 31, 2099

Ongoing

Project leader: Huober Jens
Members: Demmer-Steingruber Ruth, Müller Fiona

Es handelt sich nicht um eine Interventions- sondern um eine Beobachtungsstudie, deren Ziel es ist die Versor-gungsqualität von Patienten mit Hodenkrebs in der Schweiz zu verbessern. Anliegen ist, die Baselinecharakteristika der Patienten zu kennen,...

Clinical Studies - Jan 5, 2014 - Dec 31, 2026

Ongoing

Project leader: Rothermundt Christian
Members: Wittwer Yvonne, Müller Fiona

A phase III, multicenter, randmozed, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum do...

Clinical Studies - Dec 5, 2013 - Oct 14, 2015

Automatically Closed

Project leader: Früh Martin
Members: Munz Jeannine, Müller Fiona

A randomized, open-label, multicentre, two-arm phase III comparative study assessing the role of involved mediastinal radiotherapy after Rituximab containing chemotherapy regimens to patients with newly diagnosed Primary Mediastinal Large B-Cell Lymp...

Clinical Studies - Sep 25, 2013 - Dec 31, 2099

Ongoing

Project leader: Fehr Martin
Members: Munz Jeannine, Müller Fiona

A randomized multicenter, double-blind, placebo-controlled comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with operable HER2-positive primary breast cancer...

Clinical Studies - Mar 13, 2012 - Dec 31, 2099

Ongoing

Project leader: Ruhstaller Thomas
Members: Demmer-Steingruber Ruth, Müller Fiona